Summary
Synopsis
Fluticasone propionate is a potent topical anti-inflammatory corticosteroid with low systemic activity. Available pharmacodynamic data are only preliminary; however, large placebo- and drug-controlled clinical studies involving almost 4000 patients with seasonal allergic rhinitis and 1500 with perennial allergic and nonallergic rhinitis have confirmed the efficacy of intranasal fluticasone propionate in the control of nasal symptoms. Fluticasone propionate generally demonstrated similar efficacy compared with intranasal beclomethasone dipropionate, flunisolide acetonide and oral astemizole and better or a trend towards better efficacy compared with oral loratadine, terfenadine, cetirizine and intranasal sodium cromoglycate (cromolyn sodium) against nasal symptoms.
The incidence of adverse effects in association with intranasal fluticasone propionate appears to be comparable to that observed with placebo; the most frequently reported effects are nasal dryness/burning, epistaxis and headache. Consistent with its minimal systemic availability, intranasal fluticasone propionate in a dosage of up to 4 mg/day does not cause adrenal suppression.
Thus, based on early data from large clinical trials, fluticasone propionate administered once daily offers an effective and convenient treatment option in patients with seasonal and perennial allergic rhinitis, and is distinguished by its low oral bioavailability.
Pharmacodynamic Properties
Fluticasone propionate has potent topical anti-inflammatory activity coupled with low systemic activity. It has more than 9 times the anti-inflammatory activity of fluocinolone acetonide, and twice the activity of beclomethasone dipropionate in the McKenzie skin vasoconstriction assay in humans.
After allergen challenge, 2 weeks’ pretreatment with intranasal fluticasone propionate 200 μg/ day did not significantly inhibit the immediate increase in nasal airways resistance in atopic patients; no data concerning the possible effects of fluticasone propionate on the late and rechallenge phases of the allergic response are available.
A reduction in the number of nasal eosinophils, basophils and neutrophils has been observed in patients with seasonal allergic rhinitis after treatment with intranasal fluticasone propionate 50 to 800 μg/day administered for 2 weeks to 6 months. Further investigation revealed that the number of activated eosinophils in the nasal mucosa during the immediate allergic response was reduced after treatment with fluticasone propionate 200 μg/day, suggesting that fluticasone propionate may act by preventing eosinophil activation.
Although intravenous fluticasone propionate 2mg produced a marked reduction in plasma cortisol levels, no such effects were evident after oral administration of fluticasone propionate 16mg or after intranasal fluticasone propionate 4 mg/day for 7 days. No suppression of pituitaryadrenal function was reported after up to 12 months’ treatment with intranasal fluticasone propionate 50 to 1600 μg/day in patients involved in 9 large clinical trials.
Pharmacokinetic Properties
Fluticasone propionate is poorly absorbed following oral administration. The small portion of drug which is absorbed is metabolised rapidly and has a total blood clearance (plasma clearance adjusted for packed cell volume) almost equivalent to hepatic blood flow. Thus, the hepatic extraction ratio of fluticasone propionate is almost unity, giving the drug an oral bioavailability of < 1%. For a drug intended to have only local effects, this compares favourably with budesonide (11%), flunisolide (20%) and dexamethasone and prednisolone (> 80%), as low drug bioavailability minimises systemic adverse effects. There are no investigations concerning the pharmacokinetics of intranasal fluticasone propionate.
87 to 100% of an oral dose of fluticasone propionate is excreted in the faeces, 3 to 40% as the inactive 17β-carboxylic acid metabolite.
Therapeutic Efficacy
Extensive placebo-controlled studies involving large numbers of patients have established the efficacy of intranasal fluticasone propionate 200 μg/day in both adults and children with seasonal allergic rhinitis. Further, fluticasone propionate 200 μg/day in a once daily dose has almost equal efficacy to 100μg twice daily according to the results of 5 studies involving over 1000 patients. Topical fluticasone propionate produces a significant improvement in nasal symptoms, assessed by patients and/or clinicians, although effects on ocular symptoms have been inconsistent. Improvement is evident within 1 to 3 days of initiating treatment. In an overview of 2 large studies involving over 500 patients, 54 to 66% of fluticasone propionate 200 μg/day recipients showed symptom improvement versus 25 to 36% of placebo recipients.
In comparative studies, fluticasone propionate generally showed efficacy similar to that of intranasal beclomethasone dipropionate and flunisolide acetonide. Fluticasone propionate also achieved better control of nasal symptoms compared with oral loratadine, cetirizine and intranasal sodium cromoglycate, tended to be better than oral terfenadine and had similar efficacy to oral astemizole. Oral astemizole achieved better control of ocular symptoms than intranasal fluticasone propionate.
Fluticasone propionate 200 μg/day administered for 6 or 12 months was effective in the treatment of perennial allergic rhinitis, and showed similar efficacy to intranasal beclomethasone dipropionate in 2 comparative studies in this patient group. Limited data concerning patients with perennial nonallergic rhinitis suggest that fluticasone propionate 200 μg/day is effective, but more experience in this area is required. No data concerning the use of fluticasone propionate in the treatment of nasal polyps, nonallergic rhinitis with eosinophils syndrome or rhinitis medicamentosa are available.
Tolerability
Intranasal fluticasone propionate appears to be well tolerated by both adults and children. Adverse events are restricted predominantly to local effects such as nasal dryness, burning and epistaxis, and have been reported at a rate of 0 to 6% which is comparable to that observed with placebo (2 to 4%). There have been no reports to date of oropharyngeal candidiasis, nasal septal perforation or adrenal suppression in association with intranasal fluticasone propionate. Comparative studies indicate that the incidence of adverse events is similar with intranasal beclomethasone dipropionate and fluticasone propionate. One study documented a higher incidence of stinging with intranasal flunisolide acetonide than with fluticasone propionate or placebo.
Dosage and Administration
The recommended dose of intranasal fluticasone propionate for prophylaxis and treatment of seasonal allergic rhinitis and perennial allergic and nonallergic rhinitis is 200μg once daily in adults and children over 12 years of age. Half this dose is recommended in children aged 4 to 11 years with seasonal allergic rhinitis; currently there are insufficient data to recommend the use of intranasal fluticasone propionate for perennial rhinitis in this age group. During periods of heavy allergen challenge, additional therapy may be required to control symptoms, notably eye symptoms.
Similar content being viewed by others
References
Andersson M, Svensson C, Andersson P, Pipkorn U. Objective monitoring of the allergic inflammatory response of the nasal mucosa in patients with hay fever during natural allergen exposure. American Review of Respiratory Disease 139: 911–914, 1989
Banov C, Blumenthal M, Frazer H, Gold B, LaForce C, et al. Treatment of perennial allergic rhinitis with fluticasone propionate. Annals of Allergy 66: 97, 1991
Bauer K, Bantje TA, Sips AP, Bogaerts YJM, Gillard C, et al. The effect of inhaled fluticasone propionate (FP), a new potent corticosteroid in severe asthma. European Respiratory Journal 1 (Suppl. 2): P201s, 1988
Belling U. Once daily treatment with fluticasone propionate aqueous nasal spray or astemizole tablets for seasonal rhinitis. Clinical and Experimental Allergy 20 (Suppl. 1): 98, 1990
Bousquet J. Fluticasone propionate aqueous nasal spray versus sodium cromoglycate nasal spray in seasonal rhinitis. Clinical and Experimental Allergy 20 (Suppl. 1): 102, 1990
Bousquet J, Chanez P, Michel FB. Pathophysiology and treatment of seasonal allergic rhinitis. Respiratory Medicine 84 (Suppl. A): 11–17, 1990
Carpani de Kaski M, Peters AM, Lavender JP, Hodgson HJF. Fluticasone propionate in Crohn’s disease. Gut 32: 657–661, 1991
Chervinsky P, Bronsky E, Dockhorn R, LaForce C, Noonan M, et al. Fluticasone propionate (FP) aerosol in asthma. Abstract. Journal of Allergy and Clinical Immunology 87: 255, 1991
Clark TJH. Safety of inhaled corticosteroids. European Journal of Respiratory Diseases 63 (Suppl. 122): 235–242, 1982
Darnell R. Multicentre study of fluticasone propionate aqueous nasal spray and terfenadine tablets in seasonal rhinitis. Clinical and Experimental Allergy 20 (Suppl. 1): 101, 1990
Davies RJ. Mast cells and allergic rhinitis. Clinical and Experimental Allergy 21 (Suppl. 1): 248–252, 1991
Dockhorn R, Meltzer E, Pauli B, van As A, Weakley S, et al. Fluticasone propionate aqueous nasal spray given once a day safely controls the symptoms of seasonal allergic rhinitis. Annals of Allergy 64: 77, 1990
Dolovich J, Anderson M, Chodirker W, Drouin M, Hargreave FE, et al. Fluticasone propionate: a large multicentre trial. Respiratory Medicine 84 (Suppl. A): 31–32, 1990
Feather I, Wilson S, Brewster H, Howarth P. The clinical efficacy of fluticasone propionate aqueous nasal spray in seasonal allergic rhinitis. Abstract. Schweizerische Medizinische Wochenschrift 121 (Suppl. 40/11): 20, 1991
Grossman J, Banov C, Bronsky E, Findlay S, Mendelson L, et al. Fluticasone propionate is safe and effective for children with seasonal allergic rhinitis. Annals of Allergy 66 (Suppl. 1): 97, 1991
Harding SM. The human pharmacology of fluticasone propionate. Respiratory Medicine 84 (Suppl. A): 25–29, 1990
Hawthorne AB, Record CO, Holdsworth CD, Keech MI, Hawkey CJ. Fluticasone propionate versus prednisolone in the treatment of active ulcerative colitis: a multicentre study. Gut 32: A560–A561, 1991
Haye R. The safety and efficacy of fluticasone propionate aqueous nasal spray: a one year multicentre comparison with beclo-methasone dipropionate. Abstract. Schweizerische Medizinische Wochenschrift 121 (Suppl. 40/II): 20, 1991
Holgate ST. The mast cell and its function in allergic disease. Clinical and Experimental Allergy 21 (Suppl. 3): 11–16, 1991
Holmberg K, Juliusson S, Karlsson G, Baumgarten CR, Enerbäck L, et al. Effects of 4 weeks treatment with the topical gluco-corticoid fluticasone on allergen-induced symptoms, tissue mast cells and histamine in the nasal mucosa. XIV International Congress of Allergology and Clinical Immunology, Kyoto, October 13–18, 1991. Abstract no. 183, 1991
Howarth PH, Rajakulasingam K, Feather IH. Mediators and allergic rhinitis. Clinical and Experimental Allergy 21 (Suppl. 1): 262–266, 1991
Jackson RT, Todd NW, Turner Jr JS. Ear, Nose and Throat Diseases. In Speight TM (Ed) Avery’s Drug Treatment. Principles and Practice of Clinical Pharmacology and Therapeutics, pp. 360–386, Adis Press Ltd, New Zealand 1987
Jewell DP. The new steroids: clinical experience in ulcerative colitis. Mount Sinai Journal of Medicine 57: 293–296, 1990
Johannessen TA. A comparison of fluticasone propionate, flunisolide and placebo in patients with seasonal allergic rhinitis to birch pollen — a multicentre trial. Clinical and Experimental Allergy 20 (Suppl. 1): 102, 1990
Juliusson S, Pipkorn U, Enerbäck L. Nasal eosinophils and mast cells after allergen challenge. Clinical and Experimental Allergy 20 (Suppl. 1): 8, 1990
Kaliner M, Eggleston PA, Mathews KP. Rhinitis and asthma. Journal of the American Medical Association 258: 2851–2873, 1987
LaForce C, Dockhorn R, Findlay S, Meltzer E, Nathan R, et al. Fluticasone propionate treatment for seasonal allergic rhinitis is safe and effective in adults and adolescents. Abstract. Journal of Allergy and Clinical Immunology 87: 153, 1991
Lumry W, Ahrens R, Dockhorn R, Galant S, Martin B, et al. Fluticasone propionate is safe and effective for children with seasonal allergic rhinitis. Abstract. Journal of Allergy and Clinical Immunology 87: 152, 1991
Lund V, Stokes T, Davies B, Frankland W, Delaney J, et al. A placebo-controlled study of fluticasone propionate and beclo-methasone dipropionate in seasonal rhinitis. Clinical and Experimental Allergy 20 (Suppl. 1): 102, 1990
Malmberg H, Holopainen E. Fluticasone propionate once daily in patients with seasonal rhinitis: a European multi-centre study. Clinical and Experimental Allergy 29 (Suppl. 1): 102, 1990
Meltzer EO, Orgel HA, Bronsky EA, Furukawa CT, Grossman J, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. Journal of Allergy and Clinical Immunology 86: 221–230, 1990
Meltzer EO, Schatz M. Pharmacotherapy of rhinitis 1987 and beyond. Immunology and Allergy Clinics of North America 7: 57–91, 1987
Mitchison HC, Mardini HA, Gillespie S, Laker M, Zaitoun A, et al. A pilot study of fluticasone propionate in untreated coeliac disease. Gut,32: 260–265, 1991
Munk Z, Graft D, Green A, Hampel F, Pearlman D, et al. Fluticasone propionate is an effective treatment for seasonal allergic rhinitis in adolescents. Annals of Allergy 66: 97, 1991
Naclerio RM. The pathophysiology of allergic rhinitis: impact of therapeutic intervention. Journal of Allergy and Clinical Immunology 82: 927–934, 1988
Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson Jr NF, Meyers DA, et al. Mediator release after nasal airway challenge with allergen. American Review of Respiratory Disease 128: 597–602, 1983
Nathan RA, Bronsky EA, Fireman P, Grossman J, LaForce CF, et al. Once daily fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis. Annals of Allergy 67: 332–338, 1991
Nathan RA, Bronsky EA, Fireman P, Grossman J, LaForce CF, et al. A study of onceversus twice-daily intranasal fluticasone propionate in the treatment seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology 85: 163, 1990
Orgel HA, Meltzer EO, Doyle VR, Field E. Topical intranasal corticosteroid (fluticasone propionate) decreases cells of allergy and inflammation in nasal mucosa of patients with seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology 85: 162, 1990
Pelikan Z, Pelikan-Filipek M. Cytologic changes in the nasal secretions during the immediate nasal response. Journal of Allergy and Clinical Immunology 82: 1103–1112, 1988
Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respiratory Medicine 84 (Suppl. A): 19–23, 1990
Pipkorn U, Karlsson G, Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure. Journal of Allergy and Clinical Immunology 82: 1046–1054, 1988
Ramsdale EH, Kline PA. Comparison of once daily treatment with an antihistamine (loratadine) and topical steroid (fluticasone propionate) during the ragweed pollen season. Journal of Allergy and Clinical Immunology 87: 298, 1991
Ratner PH, Pauli BR, Findlay SR, Rogenes PR. Fluticasone propionate OD is as effective as beclomethasone dipropionate BD in relieving symptoms of seasonal allergic rhinitis. Clinical and Experimental Allergy 20 (Suppl. 1): 98, 1990
Rogenes P, van As A, Kral K. Fluticasone propionate 200 mcg once a day relieves symptoms of allergic rhinitis within 24 to 48 hours. Allergy and Clinical Immunology News (Suppl. 1): 337, 1991
Scadding G, Lund V. A multicentre placebo controlled study of fluticasone propionate and beclomethasone dipropionate in perennial rhinitis. Abstract. Schweizerische Medizinische Wochenschrift 121 (Suppl. 40/I): 17, 1991
Scadding GK, Lund VJ, Holmstrom M, Darby YC. Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology (Suppl. 11): 37–43, 1991
Schleimer RP. The mechanisms of antiinflammatory steroid action in allergic diseases. Annual Review of Pharmacology and Toxicology 25: 381–412, 1985
Siegel SC. Topical intranasal corticosteroid therapy in rhinitis. Journal of Allergy and Clinical Immunology 81: 984–991, 1988
Small P, Biskin N, Barrett D. The effects of intranasal fluticasone propionate on allergen induced nasal provocation. Clinical and Investigative Medicine 12 (Suppl. 4): B5, 1989
Thomas KE, Greenwood L, Murrant N, Cook J, Devalia JL, et al. The effects of topical fluticasone propionate on allergen-induced immediate nasal airways response and eosinophil activation: preliminary results. Respiratory Medicine 84 (Suppl. A): 33–35, 1990
van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Annals of Allergy 67: 156–162, 1991
van As A, Bronsky E, Chervinsky P, Dockhorn R, Furukawa C, et al. Fluticasone propionate once daily is as effective as beclomethasone dipropionate twice daily for perennial allergic rhinitis. Abstract. Journal of Allergy and Clinical Immunology 87: 154, 1991
van Bavel J, Findlay SR, Hampel F, Martin B, Ratner P, et al. Intranasal fluticasone propionate once daily is more effective than terfenadine twice daily in relieving symptoms of seasonal allergicrhinitis. Abstract. Journal of Allergy and Clinical Immunology, in press, 1992
Vervloet D, Charpin D, Desfougeres JL. Fluticasone propionate aqueous nasal spray versus cetirizine (C) in seasonal rhinitis. European Respiratory Journal 4 (Suppl. 14): 436s, 1991
Wang JH, Duddle J, Thomas KE, Lozewicz S, Devalia JL, et al. Effect of topical fluticasone propionate on allergen induced inflammatory cell changes in the nose. Thorax 46: 781P, 1991
Weakley S, Rogenes P, Field E. Intranasal fluticasone propionate treatment for perennial non-allergic rhinitis. Abstract. Journal of Allergy and Clinical Immunology 87: 218, 1991
Williams PL, Warwick R, Dyson M, Bannister LH (Eds) Gray’s Anatomy, 37th ed., Churchill Livingstone, 1989
Zaitoun A, Record CO. Morphometric studies in duodenal biopsies from patients with coeliac disease: the effect of the steroid fluticasone propionate. Alimentary Pharmacology and Therapeutics 5: 151–160, 1991
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: J. Bousquet, Hôpital de PAiguelongue, Montpellier, France; J. Dolovich, McMaster University, Hamilton, Ontario, Canada; T.A. Johannessen, Horten ENT Centre, Horten, Norway; M. Kaliner, National Institutes of Health, Bethesda, Maryland, USA; S. Lozewicz, Department of Respiratory Medicine and Allergy, St Bartholomew’s Hospital, London, England; S. Makino, Dokkyo University School of Medicine, Mibu, Tochigi, Japan; H. Malmberg, Ear, Nose and Throat Clinic, Helsinki University Central Hospital, Helsinki, Finland; M. Okuda, Nippon Medical School, Tokyo, Japan; D.S. Pearlman, Colorado Allergy and Asthma Clinic, Aurora, Colorado, USA; A.S. Rebuck, Asthma Centre, The Toronto Hospital, Toronto Western Division, Toronto, Ontario, Canada; G.K. Scadding, The Royal National Throat, Nose and Ear Hospital, London, England; P. Small, The Sir Mortimer B. Davis — Jewish General Hospital, Montreal, Quebec, Canada.
Rights and permissions
About this article
Cite this article
Bryson, H.M., Faulds, D. Intranasal Fluticasone Propionate. Drugs 43, 760–775 (1992). https://doi.org/10.2165/00003495-199243050-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199243050-00009